



December 28, 2016

Sammy Almashat, MD., M.P.H.
Public Citizen's Health Research Group
1600 20th Street, N.W.
Washington, DC 20009

Dear Petitioner:

Your petition to the Food and Drug Administration requesting that the FDA take immediate action with respect to the label of repaglinide-containing medications (PRANDIN, PRANDIMET) was received by this office on 12/27/2016. It was assigned docket number FDA-2016-P-4584 and it was filed on 12/28/2016. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

A handwritten signature in cursive script, appearing to read "D Bigby".

Dynna Bigby
Supervisory Administrative Proceedings Specialist
Division of Dockets Management
FDA/Office of the Executive Secretariat (OES)

CC: Michael Carome, M.D., Director, Public Citizen's Health Research Group
Sidney Wolfe, M.D., Founder/Sr Adviser, Public Citizen's Health Research Group